(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Rep. Mike Collins (R-Ga.) heavily criticized statements made by the Right Rev. Mariann Budde on Tuesday at the inaugural ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback